NasdaqCM - Nasdaq Real Time Price USD

Mereo BioPharma Group plc (MREO)

2.9600

-0.0100

(-0.34%)

At close: May 14 at 4:00 PM EDT

MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks last month

MREO
-0.34%
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST. A live audio webcast of the presentation can be accessed through the Investors section of the Compa

GlobeNewswire last month

MREO
-0.34%
Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results

Setrusumab and Alvelestat Progress as Company Prepares for Transformative 2024

GuruFocus.com last month

MREO
-0.34%
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partner around the end of 2024 Cash of $57.4 million as of December 31, 2023 expected to fund operations into 2026 LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “

GlobeNewswire last month

MREO
-0.34%
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 11:20am ET / 03:20pm GMT. A live audio webcast of the presentation can be accessed through the Investors section of the Company’s

GlobeNewswire 2 months ago

MREO
-0.34%
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat

Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.

Zacks 2 months ago

RARE

MREO
-0.34%
15 Top Performing European Stocks So Far in 2024

In this piece, we will take a look at the 15 top performing European stocks so far in 2024. If you want to skip our overview of the European economy and the stock climate, then you can skip ahead to 5 Top Performing European Stocks So Far in 2024. Over the course of the past […]

Insider Monkey 2 months ago

^FTSE

^GSPC

MRUS
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint

Ultragenyx (RARE) reports preliminary full-year 2023 revenues, along with business updates, and shares 2024 revenue guidance.

Zacks 4 months ago

RARE

ADMA

MREO
-0.34%
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024 Alignment on design for single, global Phase 3 study of alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) following additional interactions with U.S. FDA in 2H 2023 Signs global licensing deal for

GlobeNewswire 4 months ago

RARE

MREO
-0.34%
Hedge Funds Say These Penny Stocks Are Poised to Explode

In this article, we will take a detailed look at hedge funds say these penny stocks are poised to explode. To see more such stocks, click Hedge Funds Say These 5 Penny Stocks are Poised to Explode. Despite common belief, not all penny stocks are inherently risky and suitable only for short-term gains. Some penny stocks […]

Insider Monkey 4 months ago

MREO
-0.34%
MXCT

TTI
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates

Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook.

Zacks 6 months ago

RARE

MREO
-0.34%
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information. Recent Program Developments Setrusumab (UX143) On October 14, 2023, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (“Mereo” or the “Company”) announced interim data from the Phase 2 portion

GlobeNewswire 6 months ago

MREO
-0.34%
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase

GlobeNewswire 6 months ago

MREO
-0.34%
RARE
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR) October 13-16, 2023, in Vancouver, British Columbia. Ultragenyx and its collaborators will present late-breaking presentations on new, updated data from the Phase 2 portion of the

GlobeNewswire 7 months ago

MREO
-0.34%
RARE
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST. A live audio webcast of the presentation can be accessed through the Investors section of the Company’

GlobeNewswire 7 months ago

MREO
-0.34%
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its unaudited interim financial results for the six months ended June 30, 2023 and provided an update on recent corporate highlights. “The first half of 2023 was highlighted by significant updates on each of our lead rare disease programs, as we announced, alongside our partner Ultragenyx, positive dat

GlobeNewswire 8 months ago

MREO
-0.34%
BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC

Firm real-time pick highlight

GuruFocus.com 8 months ago

MREO
-0.34%
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat

Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.

Zacks 9 months ago

RARE

MREO
-0.34%
ADCT
Ultragenyx (RARE) Doses First Patients in Bone Disease Studies

Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.

Zacks 10 months ago

RARE

MREO
-0.34%
AKRO
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients NOVATO, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patients have been dosed in both of its late-stage clinical trials evaluating setrusumab in pediatric and young adult patients with OI sub-types I, III and IV. The Phase 3

GlobeNewswire 10 months ago

RARE

MREO
-0.34%

Performance Overview

Return	MREO	MSCI WORLD
YTD	+28.14%	+8.49%
1-Year	+157.39%	0.00%
3-Year	-4.52%	+17.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mereo BioPharma Group plc (MREO)

MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat

15 Top Performing European Stocks So Far in 2024

Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Hedge Funds Say These Penny Stocks Are Poised to Explode

Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC

Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat

Ultragenyx (RARE) Doses First Patients in Bone Disease Studies

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Performance Overview